dicloxacillin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, 6-aminopenicillanic acid derivatives 866 3116-76-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dicloxacillin
  • dicloxacycline
  • dicloxacillin sodium
  • dicloxacillin sodium hydrate
  • dicloxacillin sodium monohydrate
One of the PENICILLINS which is resistant to PENICILLINASE.
  • Molecular weight: 470.32
  • Formula: C19H17Cl2N3O5S
  • CLOGP: 3.02
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 112.74
  • ALOGS: -4.20
  • ROTB: 3
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g O
2 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 60 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 35.51 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 67.50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.11 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.03 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.88 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.193 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 11.246 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.904 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 3.837 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 13.980 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 15.010 % High 1
herg hERG pIC50 4.315 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 4.786 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 4.853 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 6.100 % High 1
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,GRK3,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 46
kinase-selectivity-class AXL,EIF2AK3,GRK2 3
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.897 High 1
mh-clint Mouse hepatocyte intrinsic clearance 15.704 High 1
mppb Mouse plasma protein binding (% unbound) 5.800 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 3.589 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 6.390 % High 1
rh-clint Rat hepatocyte intrinsic clearance 6.761 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 64.110 % High 1
rppb Rat plasma protein binding (% unbound) 4.360 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 984.011 uM High 1

Approvals:

DateAgencyCompanyOrphan
April 22, 1968 FDA WYETH AYERST

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tubulointerstitial nephritis 97.40 31.76 24 537 25319 90602567
Suspected transmission of an infectious agent via product 48.59 31.76 7 554 398 90627488
Drug hypersensitivity 34.66 31.76 26 535 463583 90164303

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Prothrombin time shortened 44.49 40.49 8 300 1581 42619446

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tubulointerstitial nephritis 110.27 30.22 33 870 54251 110534145
Suspected transmission of an infectious agent via product 78.58 30.22 13 890 1387 110587009
Acute kidney injury 39.46 30.22 36 867 635394 109953002
Pyrexia 34.07 30.22 39 864 898226 109690170

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01CF01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
BETA-LACTAM ANTIBACTERIALS, PENICILLINS
Beta-lactamase resistant penicillins
FDA CS M0016152 Penicillins
FDA EPC N0000175497 Penicillin-class Antibacterial
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:36047 antibacterial drug

Related Drugs by ATC class:

J01CF Beta-lactamase resistant penicillins 5 drugs
cloxacillinfloxacillinmeticillinnafcillinoxacillin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Infection of skin AND/OR subcutaneous tissue indication 19824006
Staphylococcal pneumonia indication 22754005
Acute bacterial sinusitis indication 75498004
Infection due to Staphylococcus aureus indication 406602003
Staphylococcus Aureus Bronchitis indication
Continuation Therapy for Chronic Osteomyelitis indication
Continuation Therapy for Acute Osteomyelitis indication
Pyrexia of unknown origin off-label use 7520000
Diabetic Foot Infection Due to Gram-Positive Bacteria off-label use
Kidney disease contraindication 90708001 DOID:557
Infectious mononucleosis contraindication 271558008 DOID:8568
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

SpeciesUseRelation
Dogs Pyoderma (pyogenic dermatitis) caused by penicillinase-producing staphylococci Indication

🐶 Veterinary products

ProductApplicantIngredients
Dicloxin Capsules Zoetis Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.76 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Muscarinic acetylcholine receptor M1 GPCR IC50 5.96 WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR IC50 5.66 WOMBAT-PK
Muscarinic acetylcholine receptor M3 GPCR IC50 5.60 WOMBAT-PK
Histamine H2 receptor GPCR IC50 4.80 WOMBAT-PK
Bile salt export pump Transporter IC50 4.16 CHEMBL
cGMP-dependent 3',5'-cyclic phosphodiesterase Enzyme IC50 4.42 WOMBAT-PK
Sodium-dependent dopamine transporter Transporter IC50 4.11 WOMBAT-PK
Penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL
Penicillin-binding protein 1A Enzyme WOMBAT-PK
Streptokinase A Enzyme EC50 7.22 WOMBAT-PK

External reference:

IDSource
4019715 VUID
N0000147807 NUI
D02137 KEGG_DRUG
13412-64-1 SECONDARY_CAS_RN
267257 RXNORM
4017842 VANDF
4019715 VANDF
C0012093 UMLSCUI
CHEBI:4511 CHEBI
CHEMBL893 ChEMBL_ID
CHEMBL1200701 ChEMBL_ID
D004009 MESH_DESCRIPTOR_UI
DB00485 DRUGBANK_ID
12261 IUPHAR_LIGAND_ID
1984 INN_ID
COF19H7WBK UNII
18381 PUBCHEM_CID
1016 MMSL
4585 MMSL
d00153 MMSL
002703 NDDF
002704 NDDF
372873001 SNOMEDCT_US
70886000 SNOMEDCT_US
8416000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dicloxacillin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0093-3123 CAPSULE 250 mg ORAL ANDA 19 sections
Dicloxacillin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0093-3125 CAPSULE 500 mg ORAL ANDA 19 sections
Dicloxacillin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0440-1380 CAPSULE 250 mg ORAL ANDA 21 sections
Dicloxacillin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0440-7380 CAPSULE 250 mg ORAL ANDA 19 sections
Dicloxacillin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 16590-076 CAPSULE 500 mg ORAL ANDA 12 sections
Dicloxacillin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 21695-124 CAPSULE 250 mg ORAL ANDA 21 sections
Dicloxacillin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 33261-167 CAPSULE 250 mg ORAL ANDA 20 sections
Dicloxacillin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 43063-180 CAPSULE 250 mg ORAL ANDA 19 sections
Dicloxacillin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 43063-180 CAPSULE 250 mg ORAL ANDA 19 sections
Dicloxacillin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 43063-473 CAPSULE 500 mg ORAL ANDA 19 sections
Dicloxacillin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 43063-473 CAPSULE 500 mg ORAL ANDA 19 sections
Dicloxacillin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 52959-049 CAPSULE 500 mg ORAL ANDA 19 sections
Dicloxacillin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 54868-0937 CAPSULE 250 mg ORAL ANDA 21 sections
Dicloxacillin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 54868-1380 CAPSULE 500 mg ORAL ANDA 21 sections
Dicloxacillin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 55289-592 CAPSULE 250 mg ORAL ANDA 19 sections
Dicloxacillin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 55289-592 CAPSULE 250 mg ORAL ANDA 19 sections
DICLOXACILLIN SODIUM Human Prescription Drug Label 1 59651-565 CAPSULE 250 mg ORAL ANDA 20 sections
DICLOXACILLIN SODIUM Human Prescription Drug Label 1 59651-566 CAPSULE 500 mg ORAL ANDA 20 sections
DICLOXACILLIN SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 62135-096 CAPSULE 250 mg ORAL ANDA 11 sections
DICLOXACILLIN SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 62135-097 CAPSULE 500 mg ORAL ANDA 11 sections
Dicloxacillin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 63629-4256 CAPSULE 500 mg ORAL ANDA 19 sections
Dicloxacillin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 66267-073 CAPSULE 500 mg ORAL ANDA 20 sections
Dicloxacillin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 67296-0122 CAPSULE 500 mg ORAL ANDA 19 sections
Dicloxacillin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 67296-1205 CAPSULE 500 mg ORAL ANDA 12 sections
Dicloxacillin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 76420-183 CAPSULE 500 mg ORAL ANDA 19 sections